Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, a move that comes as the company approaches a critical milestone with its lead drug candidate, buntanetap. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across the company's Alzheimer's disease (AD) and Parkinson's disease (PD) programs. His responsibilities include translational science, clinical development, biomarker strategy, and regulatory interactions.
The promotion signals Annovis's readiness to advance buntanetap toward top-line data from its pivotal Phase 3 Alzheimer's disease study and a subsequent New Drug Application (NDA) submission. According to the company, Fang has played a key role in advancing clinical development efforts and will lead scientific strategy through upcoming clinical and regulatory milestones. This leadership change is likely to reassure investors and stakeholders that Annovis is strengthening its executive team to navigate the complex regulatory landscape.
Buntanetap, an investigational once-daily oral therapy, works by inhibiting the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases.
The importance of this news lies in the potential impact of buntanetap on the Alzheimer's and Parkinson's disease treatment landscape. If successful, buntanetap could offer a novel therapeutic option that targets multiple toxic proteins simultaneously, differentiating it from existing treatments that typically focus on a single protein. For industry leaders and investors, the promotion of a seasoned scientist like Fang may signal enhanced focus on rigorous scientific execution and regulatory preparedness. The company's progress toward an NDA submission could also influence the broader biotech sector, particularly for companies developing RNA-targeting therapies.
For more information, visit Annovis Bio and follow the company on LinkedIn, YouTube, and X. The full press release is available at https://ibn.fm/c9jdt.
